¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2021 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2021)-4¿ù 1ÀÏ : 2021-04-01

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2021 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2021)-4¿ù 1ÀÏ : 2021-04-01
±³À°ÀÏÀÚ : 2021-04-01
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2021 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2021)-4¿ù 1ÀÏ      
ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
´ã´çÀÚ : À±ÁöÇý
¿¬¶ôó : 02-566-6031  
À̸ÞÀÏ : hematology@kams.or.kr      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú      
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 150,000¿ø      
ºñ°í ´ëÇÑÇ÷¾×ÇÐȸ ȸ¿ø £Ü50,000, Æç·Î¿ì/°£È£»ç/¿¬±¸¿ø £Ü30,000Çлý/Àü°øÀÇ £Ü20,000, ºñȸ¿ø £Ü150,000      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04¿ù 01ÀÏ Room 1 09:00~09:30 Contemporary Treatment of Pediatric Ph+ ALL  Kirk Schultz(University of British Columbia Canada) 
±³À°½Ã°£ 04¿ù 01ÀÏ Room 1 09:30~10:00 Current Treatment Approaches to Newly Diagnosed Adult ALL  Daniel Joseph DeAngelo(Dana Farber Cancer Institute USA) 
±³À°½Ã°£ 04¿ù 01ÀÏ Room 1 10:00~10:30 Results of High Risk and Novel Subtypes of Pediatric ALL in Japan  Katsuyoshi Koh(Saitama Children's Medical Center Japan) 
±³À°½Ã°£ 04¿ù 01ÀÏ Room 1 10:30~11:15 Clonal Hematopoiesis and the Origin of Hematologic Malignancies  Benjamin Ebert(Dana-Farber Cancer Institute USA) 
±³À°½Ã°£ 04¿ù 01ÀÏ Room 1 11:30~12:10 New Treatment Option for FLT3 mutant AML  Alexander Edward Perl(University of Pennsylvania USA) 
±³À°½Ã°£ 04¿ù 01ÀÏ Room 1 12:55~13:25 From Korean Perspective  µµ¿µ·Ï(°è¸íÀÇ´ë) 
±³À°½Ã°£ 04¿ù 01ÀÏ Room 1 13:25~13:55 From Chinese Perspective  Qian Jiang(Peking University China) 
±³À°½Ã°£ 04¿ù 01ÀÏ Room 1 13:55~14:25 From Japanese Perspective  Shinya Kimura(Saga University Japan) 
±³À°½Ã°£ 04¿ù 01ÀÏ Room 2 14:40~15:00 Single Cell RNA Sequencing Reveals Tranional Programs Associated with Myeloma Progression  ÀÌÇý¿Á(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 01ÀÏ Room 2 15:00~15:20 ulti-Omics Analysis and Modeling of DNA Methylation in Cancer  ±è¼±(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04¿ù 01ÀÏ Room 2 15:20~15:45 Clinical Application of Next-Generation Sequencing in Acute Myeloid Leukemia  ¾ÈÀç¼÷(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 01ÀÏ Room 2 15:45~16:10 Challenges in the Introduction of Next-Generation Sequencing for Diagnostics of Hematologic Malignancies  À̽ÂÅÂ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 01ÀÏ Room 2 16:25~16:55 Novel Strategies to Overcome Relapsed/Refractory Multiple Myeloma  Suzanne Trudel(University of Toronto Canada) 
±³À°½Ã°£ 04¿ù 01ÀÏ Room 2 16:55~17:25 MRD Negativity - The Foremost Important Goal of Myeloma Treatment?  Bruno Paiva(University of Navarra Spain) 
±³À°½Ã°£ 04¿ù 01ÀÏ Room 2 17:25~17:50 Primary Amyloidosis  ±è±âÇö(¼º±Õ°üÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2021 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2021)-4¿ù 1ÀÏ : 2021-04-01""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) 1Çбâ À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ - ±¸°­ÀÛ¿­ÁõÈıº(Burning mouth syndrome) : 2021-04-01
´ÙÀ½±Û (¿Â¶óÀÎ) 2021 ´ëÇÑÅëÁõ¿¬±¸ÇÐȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ : 2021-03-28
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20500 ¼­¿ï 2024 Á¦2Â÷ ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸºÎÀοµ»ó¿¬±¸ Çмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-05-12 0 6 2024-04-29
20499 ¼­¿ï Çѱ¹Á¤½ÅÄ¡·áÇÐȸ Á¤½ÅÄ¡·á Áõ·Ê¹ßÇ¥ : 2024-05-11 0 8 2024-04-29
20498 ºÎ»ê ¸¸¼ºÆó¼â °ü»óµ¿¸Æ ÁßÀç½Ã¼ú¿¬±¸È¸ The 23rd K-CTO(Korean Chronic Total Occlusion Club) Live Demonstration : 2024-05-11 0 19 2024-04-29
20497 ¼­¿ï ´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11 0 4 2024-04-29
20496 ¼­¿ï 2024 ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2024-05-11 0 18 2024-04-29
20495 ¼­¿ï Á¦77Â÷ ´ëÇÑû°¢ÇÐȸ Çмú´ëȸ : 2024-05-11 0 11 2024-04-29
20494 ÀÎõ Á¦9ȸ °¡Ãµ´ë ±æº´¿ø ½Å°æ¿Ü°ú ¾÷µ¥ÀÌÆ® ½ÉÆ÷Áö¿ò (G-NeUS) : 2024-05-11 0 5 2024-04-29
20493 ´ëÀü 2024³â ´ëÇѽŰæÁßÀçÄ¡·áÀÇÇÐȸ Ãá°èÇмú´ëȸ & Basic Training Course : 2024-05-11 0 8 2024-04-29
20492 ±¤ÁÖ 2024³â ´ëÇѼҾƺñ´¢ÀÇÇÐȸ Á¦37Â÷ Çмú´ëȸDAY2 : 2024-05-11 0 6 2024-04-29
20491 ¼­¿ï Á¦50ȸ ´ëÇÑÀÓ»óÇǺÎÄ¡·á¿¬±¸È¸ ±³À°½ÉÆ÷Áö¾ö : 2024-05-11 0 14 2024-04-29
20490 ¼­¿ï ÇѾç´ëÇб³º´¿ø Á¤Çü¿Ü°ú ⸳ 52Áֳ⠱â³äÇмú´ëȸ : 2024-05-11 0 35 2024-04-29
20489 ¼­¿ï °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ¼ºÇü¿Ü°úÇб³½Ç â¸³ 50Áֳ⠱â³ä Çмú´ëȸ : 2024-05-11 0 4 2024-04-29
20488 °æ±â ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2024 Spring Semi-Annual Meeting (2ÀÏÂ÷) : 2024-05-11 0 15 2024-04-29
20487 °­¿ø 2024³â ´ëÇѺ´¸®ÇÐȸ º½Çмú´ëȸ(2ÀÏÂ÷) : 2024-05-10 0 9 2024-04-29
20486 ¼­¿ï 2024 ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Ãá°èÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-10 0 16 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷